Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Genetically modified tumor cell vaccines

F S Hodi¹, G Dranoff

¹Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Surgical Oncology Clinics of North America

|June 13, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

European journal of cancer (Oxford, England : 1990)·2024

Same author

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma<sup>☆</sup>.

ESMO open·2021

Same author

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Same author

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2017

Advancements in tumor antigen identification and host-tumor interactions are driving cancer vaccine development. Gene transfer technologies are central to these novel immunization strategies, with ongoing research exploring genetically modified tumor vaccines.

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Recent progress in identifying tumor antigens has advanced cancer vaccine research.
Understanding the host-tumor relationship is crucial for effective cancer immunotherapy.

Purpose of the Study:

To review key principles and controversies in genetically modified tumor vaccine development.
To explore future directions for cancer vaccine research.

Main Methods:

Review of recent advancements in tumor antigen identification.
Analysis of gene transfer technologies in cancer vaccine design.
Discussion of experimental findings with genetically modified tumor vaccines.

Main Results:

Related Experiment Videos

Gene transfer technologies are integral to novel cancer vaccine designs.

Significant progress has been made in understanding host-tumor interactions.

Key principles and controversies surrounding genetically modified tumor vaccines have been highlighted.

Conclusions:

The field of cancer vaccines is rapidly expanding due to progress in antigen identification and host-tumor relationship understanding.
Genetically modified tumor vaccines represent a promising area of research.
Future research should focus on addressing key principles and controversies in this field.